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1. Introduction
Most of the clinically important bacteria causing infections in humans are capable of exhibit‐
ing resistance to antimicrobial agents commonly used for the treatment. Therefore, upon iso‐
lation of the organism in the clinical microbiology laboratory, characterization frequently also
employs tests to detect its antimicrobial susceptibility. Thus, the report produced by clinical
microbiology laboratory for the physician, also includes organism’s susceptibility profile to
different antimicrobials along with its identification [1]. Antimicrobial susceptibility testing
(AST) is performed on bacteria that are isolated from clinical specimens to determine if the
bacterial etiology of concern can be killed or inhibited by antimicrobial drugs that are poten‐
tial choices for therapy, at the concentrations of the drugs that are attainable at the site of infec‐
tion using the dosing regimen indicated in the drug product’s labeling. The results of AST are
generally reported with interpretive categories. The category “susceptible” indicates that the
bacteria are inhibited by the usually achievable concentrations of antimicrobial agent when
the dosage recommended to treat the site of infection is used. The “intermediate” category de‐
fines the bacteria for which the response rates to usually attainable blood and tissue levels of
antimicrobial agent are lower compared to susceptible isolates. The intermediate category
plays the role of a buffer zone between the susceptible and resistant categories, but also indi‐
cates a number of other possibilities; the antimicrobials which are concentrated at the site of
infection may be regarded as options for treatment (e.g., nitrofurantoin for the urinary tract
infections). The “resistant” category, however, defines the bacteria which are not inhibited by
the usually achievable concentrations of the agent with normal dosage regimens and that the
clinical efficacy of the agent against the isolate may not be sufficient [2]. Clinicians consider
these interpretations to determine which antimicrobial agent might be effective in treating the
particular patient. The primary role of routine microbiology laboratories is to provide accu‐
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rate and timely antimicrobial susceptibility test results for guiding the treatment of infectious
diseases. In order to achieve that, the microbiologist should inform the clinician about wheth‐
er an infectious agent is present in the patient’s specimen and which antimicrobial agent
should provide the optimum therapy. Although the importance of antimicrobial susceptibili‐
ty testing is well established, the procedure itself is very sensitive to changes in the environ‐
ment and test conditions. Therefore, it is crucial that each variable in the procedure should be
standardized and carefully controlled. With more reliable susceptibility results, infectious dis‐
ease specialists and public health leaders can be able to recognize emerging resistance and
novel resistance patterns. Additionally, the results of AST can be applied to define the agent of
choice for empirical therapy, establish institutional or nationwide policies for prescribing of
antibiotics, conduct epidemiological studies or resistance surveillance, and to evaluate the ef‐
ficacy of newly developed agents. Owing to numerous variables that may affect the results,
rigorous quality  control  is  of  utmost  importance for  susceptibility  testing.  Properly per‐
formed quality control would aid in providing accurate, reproducible and timely results. In
this chapter the components of a quality assurance program for antimicrobial susceptibility
testing will be highlighted.
2. Overview of the antimicrobial susceptibility testing methodologies
Fleming was first to report the inhibitory effect of penicillin on agar by observing a zone of
growth inhibition of staphylococcal colonies grown next to a Penicillium contaminant on an
agar plate. Fleming also made two significant contributions to the field of AST in the 1920s.
In 1924, he introduced the use of the ditch plate technique for evaluating antimicrobial qual‐
ities of antiseptic solutions [3]. Fleming’s second contribution to modern AST was the devel‐
opment of broth dilution technique using turbidity as an end-point determination [4]. Filter
paper disks incorporating penicillin were utilized by Vincent & Vincent for assaying this
newly discovered compound in 1940s [5]. Agar dilution AST method was also described in
the 1940s [6]. At an early stage, it was realized that there were many variables affecting AST
methods [7]. In 1961, World Health Organization (WHO) published a report on standardiza‐
tion of AST methodology [8]. The broad application of AST was introduced to clinical labo‐
ratories by the efforts of Bauer, Kirby and co-workers, with the method known as Kirby-
Bauer disk diffusion method which is still the most widely used AST technique in the world
[9]. Bergeron & Ouellette highlighted the shortcomings of the phenotypic approach to AST
and concluded that different bacterial species have different susceptibilities to the same anti‐
biotic, and that there is no international aggreement on breakpoints for interpretation of an‐
timicrobial susceptibility tests [10]. The need for developing standardized AST methods
became a necessity soon after antibiotics became commercially available. During World War
II, following penicillin, other antibiotics were discovered and used. Altough these new anti‐
biotics were regarded as “wonder drugs” at the time of their introduction, emergence of re‐
sistant strains followed. With the emergence of bacterial resistance to antimicrobials and the
changing properties of different bacteria to different classes of antimicrobials, the need for
the performance of AST on pathogens became a practical necessity.
Latest Research into Quality Control414
Nationwide attempts were made to standardize AST methodologies; Clinical and Laborato‐
ry Standards Institute (CLSI, formerly NCCLS) (USA) [11], Werkgroep Richtlijnen Gevoe‐
ligheidsbepalingen (Netherlands) [12], Comité de l’Antibiogramme de la Société Française
de Microbiologie (France) [13], the Swedish Reference Group for Antibiotics (Sweden) [14],
Deutsches Institut für Normung (Germany) [15], the British Society for Antimicrobial Che‐
motherapy (UK) [16], they all published guidelines to improve the methodology and inter‐
pretation of AST. Recently, the European Committee on Antimicrobial Susceptibility Testing
(EUCAST), a non-profit organization under the auspices of European Society of Clinical Mi‐
crobiology and Infectious Diseases (ESCMID), developed and published AST guidelines.
Breakpoint and QC tables for disk diffusion and minimum inhibitory concentration (MIC)
testing can freely be accessed on organization’s website [17].
In clinical laboratories, widely adopted AST methods are disk diffusion and broth dilution
methods. In disk diffusion method, disks impregnated with antimicrobial agents are used.
The disks are placed onto agar plates which are preinoculated with the suspension of the
microorganism being tested. The basic principle of the disk diffusion method is the diffusion
of the antimicrobial agent into the medium which occurs when the disks come into contact
with the moist surface of the plate. The concentration of the agent reduces logarithmically as
the distance from the disk is increased. After the incubation period the plates are observed
for the circular inhibiton zone created around the disk which is due to the inhibitory effect
of the antimicrobial agent on the microorganism. Within the zone the concentration of the
agent is sufficient to inhibit growth, whereas at the point where the concentration of the
agent is no longer enough to inhibit growth, the organism is able to grow and forms a lawn
of bacteria around the disk. To interprete the test results, the radius of the inhibition zone is
measured and compared against the predefined values provided by the guidelines [18]. The
most widely used guidelines are the CLSI and EUCAST guidelines [2, 17]. CLSI divides the
results into three categories for most of the organism-agent combinations; susceptible, inter‐
mediate and resistant, whereas EUCAST uses only two categories, susceptible and resistant.
In the dilution methods, however, the susceptibility of the microorganisms to antimicrobial
agents is determined whether in tubes (macrobroth dilution method) or in microtube wells
molded into a plastic plate (microbroth dilution method). Both broth dilution methods use
the same principle; first serial two-fold dilutions of the antimicrobial agent to be tested are
made in the tubes/wells containing broth, and then same amount of bacterial suspension is
distributed on each tube/well. At the end of the incubation period, the tubes/wells are exam‐
ined for turbidity which is the indicator of bacterial growth in broth. The tubes/wells remain
clear where the concentration of the agent is high enough to inhibit the bacterial growth,
whereas at lower concentrations of the agent, the bacteria may grow which causes the tube/
well become turbid. The lowest concentration of antimicrobial agent that prevents the in vi‐
tro growth of bacteria is defined as the minimal inhibitory concentration (MIC) [18]. As in
the disk diffusion method, the MIC values are compared against the predefined values pro‐
vided by the guidelines and their intrepretive category is determined and reported.
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3. Quality assurance program for antimicrobial susceptibility testing
Clinical microbiology laboratories are an integral part of the total healthcare delivery sys‐
tem. Quality assurance (QA) is the overall process by which a laboratory can verify that a
laboratory does its job well. While QA and quality control (QC) share the similar purposes,
their meanings and functions are different [19]. QA can be defined as the overall program by
which the quality of the test results can be guaranteed [20]. It evaluates and ensures that
procedures provide relevant and timely data in the delivery of healthcare services. QA is
primarily concerned with broader measures and monitors the performance of laboratory in
total and covers all three phases of testing; pre-analytical, analytical and post-analytical. QC,
in the other hand, is responsible for monitoring of the analytical phase of testing only and
ensures that the daily tests are working properly [21]. QC and QA, only together provide
measures for controlling how correct the tests are being performed because QC by itself of‐
ten does not detect problems in time to prevent harmful results. For example, if >5% of En‐
terobacter, Serratia, or Citrobacter isolates are susceptible to ampicillin, it likely indicates a
problem with insufficient inoculum [22]. Although daily or weekly QC test results are in ac‐
ceptable limits, such an error can be overlooked until enough data have been accumulated
and evaluated which can sometimes take weeks.
Standard processes are required to establish quality measures to be monitored. Standardiza‐
tion of AST has been achieved by CLSI, and in part by EUCAST. The processes defined in
CLSI guidelines help clinical laboratories to perform QC tests, measure their results and pro‐
vide corrective action recommendations covering a broad spectrum of error types. Each lab‐
oratory should establish its own quality requirements for testing processes. Only with
established quality goals, laboratories can determine whether acceptable quality is being
achieved, identify processes that are not performing satisfactorily and are in need of im‐
provement, or to plan new processes to reach a specified level of quality [21]. And to ensure
that all the established quality goals are achieved, a comprehensive QA program should be
functional in a clinical laboratory.
The major components of a comprehensive QA program for AST, with the relative amount
of effort required to be spent on each component given in parantheses, can be listed as fol‐
lows [23]:
• Clinically relevant testing strategies (15%)
• Testing of reference QC strains (15%)
• Technical competency (15%)
• Organism antibiogram verification (15%)
• Supervisor review of results (15%)
• Procedure manual (10%)
• Cumulative antibiogram (5%)
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• Proficiency surveys (5%)
• Other (5%)
The goals of the QC program as set by the CLSI [24, 25] includes to monitor the following:
• the precision (repeatability) and accuracy of AST procedures
• the performance of reagents used in the tests
• the performance of persons who carry out the tests and read the results
The continuous monitorization of the performance is best achieved, but not limited to, by
the testing of QC strains.
3.1. Developing relevant antimicrobial susceptibility testing strategies
Only organisms likely to be the cause of an infection should be tested for antimicrobial sus‐
ceptibility which necessitates the differentiation should be done between the normal flora
that resides at the site of the infection and the actual organism causing the infection. Some
important factors are to be considered to decide which bacterium or bacteria from a clinical
specimen must be included in the AST; such as the body site from which the organism was
isolated, the presence of other bacteria and the quality of the specimen from which the or‐
ganism was grown, the host’s status, the ability of the bacterial species to cause infection at
the body site from which the specimen was obtained, etc. [1, 26].
3.2. Selecting antimicrobials to test and to report
Each laboratory is unique in its capability, resources, level of experience or institutional
needs. Therefore, the decision of which antimicrobials to test depends on each laboratory’s
specifications and cannot be generalized. The decision involves the opinions of infectious
diseases specialist and the pharmacist and should also be in concordance with the hospital
formulary. Generally, a laboratory defines 10 to 15 antimicrobial agents for routine testing
against various organisms or organism groups, which is called antimicrobial panel or bat‐
tery. In CLSI’s M100 documents Table 1A (Suggested Groupings of Antimicrobial Agents
With FDA Clinical Indications That Should Be Considered for Routine Testing and Report‐
ing on Nonfastidious Organisms by Clinical Microbiology Laboratories in the United States)
is a valuable source of information to refer to when such tables are to be created at the local
level [2]. Because the identity of the bacterial isolate is often not known at the time the AST
is performed, some drugs, which are inappropriate to report for that particular isolate, may
be tested. These results, however, should be supressed in the final report.
The goal of the clinical microbiology laboratory is to create a report which will direct the
clinician to use the least toxic, most cost-effective and most clinically effective agent that is
available. This is accomplished by using the selective-reporting protocol provided by the
CLSI. CLSI categorizes antimicrobial agents generally into four groups, Group A, B, C and
U. Group A includes the primary agents whose results to be reported first. The results of
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Group B drugs should be selectively reported because these are generally broader spectrum
agents. However, if the isolate is resistant to the primary agents, the patient cannot tolerate
drugs in Group A, the infection has not responded to the therapy with the primary agents, a
secondary agent would be a better clinical choice for the particular infection or that the pa‐
tient has organisms isolated from another site also, and a secondary agent might be more
appropriate for treating both organisms, then the results of Group B drugs can be reported
[26]. Group C includes alternative or supplemental agents for special cases; such as resistant
strains, for patients allergic to primary drugs, for treatment of unusual isolates or for epide‐
miological purposes. And finally, Group U, includes the agents that are used only or pri‐
marily in the treatment of urinary tract infections (e.g., nitrofurantoin, norfloxacin).
Selective-reporting, also called cascade-reporting, improves the clinical relevance of the re‐
ports produced and minimizes the selection of multiresistant strains by avoiding the use of
broad spectrum agents when narrow spectrum option is susceptible.
3.3. Standardization of the antimicrobial susceptibility testing methodology
The procedural steps of each method must be followed strictly in order to obtain reproduci‐
ble results. Standardization of AST methodology helps to optimize bacterial growth condi‐
tions so that the inhibition of growth can be attributed to the antimicrobial agent and the
effects of nutrient limitations, temperature differences or other environmental conditions
can be eliminated. And it also optimizes conditions for maintaining antimicrobial integrity
and activity so that the failure to inhibit bacterial growth can be attributed to the organism’s
resistance mechanisms [1].
The standardized components of AST include:
Bacterial inoculum size: Preparation of the inoculum is one of the most critical steps in any
susceptibility test method. Inoculum suspensions are prepared using either a log-phase or
direct-colony suspension. When direct-colony suspension method is used, 4 to 5, fresh (16-
to 24-hour old) colonies, rather than a single colony, should be selected to minimize the pos‐
sibility of testing a susceptible colony only and missing the resistant mutants dispersed in
other colonies. McFarland turbidity standards are used to standardize the number of bacte‐
ria in the inoculum. McFarland standards can be prepared by adding specific volumes of 1%
sulfuric acid and 1.175% barium chloride to obtain a barium sulfate solution with a specific
optical density. The most commonly used is the McFarland 0.5 standard, which provides
turbidity comparable with that of a bacterial suspension containing approximately 1.5 108
CFU/mL (CFU: colony-forming unit). Once standardized, the inoculum suspensions should
be used within 15 minutes of preparation. False-susceptible results may occur if too few bac‐
teria are tested, and false-resistant results may be the outcome of testing too many bacteria
[26].
Growth medium: The most frequently used growth media are Mueller-Hinton broth and Mu‐
eller-Hinton agar. The standardized variables regarding these media should include; its for‐
mulation, pH, cation concentration and thymidine content, thickness of agar (disk diffusion
test), and supplements such as blood and serum.
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Incubation conditions (atmosphere, temperature, duration): Different organisms require different
incubation conditions. Moreover, some antimicrobial agents require different incubation
length or temperature than the other disks used for the same organism (e.g., oxacillin with
Staphylococcus spp.). The user should refer to CLSI M100 tables which give detailed testing
conditions for each organism or organism group [2].
Antimicrobials concentrations to be tested: The contents of antimicrobial disks in disk diffusion
test and concentrations of antibiotic solutions to be tested in dilution tests are also included
in CLSI documents [2].
3.4. Quality control testing with reference quality control strains
Routine QC testing with a range of QC strains is the backbone of the internal QC testing. QC
strains are well characterized organisms with defined susceptibility or resistance mecha‐
nisms to the antimicrobial agent(s) tested. Testing of QC strains helps to concurrently moni‐
tor the performance of the test and ensures that the test is being performed properly. The
results obtained with the QC strains should be in predefined, acceptable ranges; for disk dif‐
fusion test, between the predefined inhibition zone diameters, and for MIC tests in prede‐
fined MIC ranges. If deviations from the acceptable limits are observed, it indicates
unacceptable performance and the source(s) of the error should be investigated. CLSI rec‐
ommends to use various QC strains for different aspects of AST. The list of QC strains can
be found in the M100 tables which are updated on a yearly basis. Because of the introduc‐
tion of new drugs, the changes effecting the existing drugs, or the emergence of new resist‐
ance mechanisms which should be investigated by the laboratory, the users are always
referred to the latest update available. The QC strains recommended by CLSI are divided in
two as being regular „QC strains“ and „supplemental QC strains“. Each laboratory perform‐
ing AST with CLSI’s reference methods should include QC strains in regular QC tests, how‐
ever, the supplemental strains are only required if they are used to assess a new test, for
training new personnel, investigation of special susceptibility or resistance characteristics,
etc., and are not required to be included in the routine QC of AST [2].
CLSI’s European counterpart, EUCAST, also publishes guidelines for the use of QC strains
for AST, however, compared with the comprehensive battery of QC strains suggested by the
CLSI, EUCAST is limited to six QC strains at the moment [27]. The guidelines of EUCAST
are continously evolving and on areas where EUCAST’s experience is not able to cover yet,
EUCAST does not refrain from making referrals to relevant CLSI documents. However, one
big difference between the QC strains recommended by CLSI and EUCAST is that, EU‐
CAST‘s recommendation for Haemophilus influenzae NCTC 8468 in contrast to CLSI’s H. in‐
fluenzae ATCC® 49247. The strain EUCAST chose as a QC strain is susceptible to β-lactam
antibiotics whose inhibition zones are easier to read than the ATCC® strain which is a β-
lactamase negative, ampicillin resistant (BLNAR) strain. The suggested QC strains by CLSI
with their specifications are listed in Table 1 [2].
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QC Strain Test(s), for which strain is primarily used
Escherichia coli ATCC® 25922 Disk diffusion and MIC of Enterobacteriaceae, Pseudomonas
aeruginosa, Acinetobacter spp., Burkholderia cepacia,
Stenotrophomonas maltophilia
MIC of other non-Enterobacteriaceae
Screening and confirmatory tests for ESBLs (negative)
Disk diffusion and MIC of Neisseria meningitidis (for ciprofloxacin,
nalidixic acid, minocycline, and sulfisoxazole)
Escherichia coli ATCC® 35218 Disk diffusion and MIC for β-lactam/β-lactamase inhibitor
combination drugs of Enterobacteriaceae, Pseudomonas aeruginosa,
Acinetobacter spp., Burkholderia cepacia, Stenotrophomonas
maltophilia, Staphylococcus spp.
MIC for β-lactam/β-lactamase inhibitor combination drugs of other
non-Enterobacteriaceae
Testing of amoxicillin-clavulanic acid for Haemophilus spp.
Klebsiella pneumoniae ATCC® 700603 Screening and confirmatory tests for ESBLs (positive)
Klebsiella pneumoniae ATCC® BAA-1705 Confirmatory test for suspected carbapenemase production in
Enterobacteriaceae (MHT positive)
Klebsiella pneumoniae ATCC® BAA-1706 Confirmatory test for suspected carbapenemase production in
Enterobacteriaceae (MHT negative)
Pseudomonas aeruginosa ATCC® 27853 Disk diffusion and MIC of Pseudomonas aeruginosa, Acinetobacter
spp., Burkholderia cepacia, Stenotrophomonas maltophilia
MIC of other non-Enterobacteriaceae
Staphylococcus aureus ATCC® 25923 Disk diffusion of Staphylococcus spp. and Enterococcus spp.
Screening test for β-lactamase production of Staphylococcus aureus
group and coagulase negative Staphylococci (negative)
Screening test for mecA-mediated oxacillin resistance using
cefoxitin in Staphylococcus aureus group and coagulase negative
Staphylococci (mecA negative; disk diffusion susceptible)
Screening test for inducible clindamycin resistance in
Staphylococcus aureus group and coagulase negative Staphylococci
with disk diffusion (D-zone test) (negative)
Screening test for high-level mupirocin resistance in Staphylococcus
aureus group (mupA negative; disk diffusion susceptible)
Staphylococcus aureus ATCC® 29213 MIC of Staphylococcus spp.
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QC Strain Test(s), for which strain is primarily used
Screening test for β-lactamase production in Staphylococcus aureus
group and coagulase negative Staphylococci (positive)
Screening test for oxacillin resistance in Staphylococcus aureus
group (susceptible)
Screening test for mecA-mediated oxacillin resistance using
cefoxitin in Staphylococcus aureus group (mecA negative; MIC
susceptible)
Screening test for inducible clindamycin resistance in
Staphylococcus aureus group, coagulase negative Staphylococci and
Streptococcus spp. β-hemolytic group with broth microdilution (no
growth)
Screening test for high-level mupirocin resistance in Staphylococcus
aureus group (mupA negative; MIC susceptible)
Staphylococcus aureus ATCC® 43300 Screening test for oxacillin resistance in Staphylococcus aureus
group (resistant)
Screening test for mecA-mediated oxacillin resistance using
cefoxitin in Staphylococcus aureus group (disk diffusion and MIC)
and coagulase negative Staphylococci (disk diffusion) (mecA
positive)
Staphylococcus aureus ATCC® BAA-976 Screening test for inducible clindamycin resistance in
Staphylococcus aureus group, coagulase negative Staphylococci and
Streptococcus spp. β-hemolytic group with broth microdilution (no
growth)
Staphylococcus aureus ATCC® BAA-977 Screening test for inducible clindamycin resistance in
Staphylococcus aureus group, coagulase negative Staphylococci and
Streptococcus spp. β-hemolytic group with broth microdilution
(growth)
Staphylococcus aureus ATCC® BAA-1708 Screening test for high-level mupirocin resistance in Staphylococcus
aureus group (mupA positive; disk diffusion and MIC resistant)
Enterococcus faecalis ATCC® 29212 MIC of Enterococcus spp.
Screening test for vancomycin MIC ≥8 µg/mL in Staphylococcus
aureus group (susceptible)
Screening test for high-level aminoglycoside resistance in
Enterococcus spp. (disk diffusion, broth microdilution, agar dilution:
susceptible)
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QC Strain Test(s), for which strain is primarily used
Screening test for vancomycin resistance in Enterococcus spp. (agar
dilution: susceptible) checking that medium is acceptable for testing
sulfonamides, trimethoprim, and trimethoprim/sulfamethoxazole
Enterococcus faecalis ATCC® 51299 Screening test for vancomycin MIC ≥8 µg/mL for Staphylococcus
aureus group (resistant)
Screening test for high-level aminoglycoside resistance in
Enterococcus spp. (broth microdilution, agar dilution: resistant)
Screening test for vancomycin resistance in Enterococcus spp. (agar
dilution: resistant)
Haemophilus influenzae ATCC® 49247 Disk diffusion and MIC of Haemophilus spp. (BLNAR; β-lactamase
negative, ampicillin resistant)
Haemophilus influenzae ATCC® 49766 Disk diffusion and MIC of Haemophilus spp. with selected
cephalosporins (β-lactamase positive)
Haemophilus influenzae ATCC® 10211 Checking growth capabilities of medium used for disk diffusion and
MIC tests for Haemophilus spp.
Neisseria gonorrhoeae ATCC® 49226 Disk diffusion and MIC of Neisseria gonorrhoeae (CMRNG;
chromosomally mediated (penicillin) resistant N. gonorrhoeae)
Streptococcus pneumoniae ATCC® 49619 Disk diffusion and MIC of Streptococcus pneumoniae (penicillin
intermediate), Streptococcus spp. β-hemolytic group Streptococcus
spp. viridans group and Neisseria meningitidis
Screening test for inducible clindamycin resistance in Streptococcus
spp. β-hemolytic group with disk diffusion (D-zone test) and broth
microdilution (negative)
Bacteroides fragilis ATCC® 25285 MIC of anaerobes
Bacteroides thetaiotaomicron ATCC® 29741 MIC of anaerobes
Clostridium difficile ATCC® 700057 MIC of anaerobes
Eubacterium lentum ATCC® 43055 MIC of anaerobes
Table 1. Quality Control Strains Suggested for Antimicrobial Susceptibility Testing by CLSI
3.5. Selection, obtaining and maintenance of reference QC strains
When selecting QC strains for routine internal QC testing; the strains that most closely re‐
semble the patient’s isolate should be tested [23]. This will provide that the drugs planned to
be tested for the patient can be concomitantly tested with the QC strain. Additionally, same
materials and testing conditions used for the clinical isolates can be evaluated. Before ob‐
taining the QC strains, laboratories should decide which strains do fit best to the laborato‐
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ry‘s procedures. For example, if a laboratory does not perform Modified Hodge Test (MHT)
to confirm suspected carbapenemase production in Enterobacteriaceae, the Klebsiella pneumo‐
niae ATCC® BAA-1705 (MHT-positive) and Klebsiella pneumoniae ATCC® BAA-1706 (MHT-
negative) strains are not necessary for that particular laboratory. QC organisms susceptible
to the tested antimicrobials are generally used but resistant QC strains are also necessary
when testing for special resistance mechanisms.
The QC strains can be obtained from various suppliers and in many formats. What impor‐
tant is, no matter in what format the strain has been received, the initial reconstitution
should be performed according to supplier’s recommendations. For long term storage, stock
cultures can be stored in a suitable stabilizer (e.g., trypticase soy broth with 10 to 15% glyc‐
erol, 50% fetal calf serum in broth, defibrinated sheep blood or skim milk) at -20°C or below
(preferably at -60°C or below). To obtain working control cultures, subcultures from the per‐
manent stock culture are made onto agar plates. Isolated colonies (4 to 5) are selected and
subcultured to an agar slant (trypticase soy agar slants for non-fastidious organisms and
chocolate agar slants for fastidious organisms) and incubated overnight. These working cul‐
tures on agar slants are stored at 2 – 8°C, for no more than three successive weeks. New
working control cultures should be prepared at least monthly from permanent stock cul‐
tures. Prior to QC testing, growth from an agar slant is subcultured to agar plates and incu‐
bated overnight. To use for QC testing, 4 to 5 isolated colonies from the plate are selected. A
new working culture should be prepared each day the QC test is being performed [2, 23].
Working control cultures can be used to monitor precision (repeatability) and accuracy of
the AST as long as no significant change in the mean zone diameter or MIC value, not attrib‐
utable to faulty methodology, is observed. Laboratories usually do not have problems with
the maintenance of susceptible QC strains owing to the stability of these strains, however,
QC strains with particular resistance mechanisms are harder to maintain since they may be
less genetically stable. Repeated subcultures can cause the loss of resistance mechanisms
and unsatisfactory performances can be experienced. Documented problems have arisen
with the QC strains which carry their specific resistance mechanism on a plasmid (e.g., E.
coli ATCC® 35218 and K. pneumoniae ATCC® 700603) [2]. Suboptimal storage conditions
and repeated cultures may cause the spontaneous loss of the plasmid encoding the β-lacta‐
mase and off-the-limit results may be encountered.
3.6. Frequency of QC testing
Appropriate QC organisms should be tested daily for all antimicrobial agents routinely in‐
cluded in the antimicrobial battery until a laboratory achieves “satisfactory performance“.
CLSI makes the definition of “satisfactory performance“ as obtaining unacceptable results in
no more than 1 out of 20 or 3 out of 30 results obtained in consecutive test days for each
antimicrobial agent/organism combination. Once this satisfactory performance is obtained, a
laboratory can convert from daily QC testing to weekly QC testing. As long as all QC test
results are within the acceptable limits, the laboratory can continue weekly testing, however
on occasions when a modification in the test is made, consecutive QC testing is required
(Table 2., adapted from reference 2).
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Day(s)* Modification in the Test
1 Start to use new shipment or lot number of disks/MIC
panels or prepared agar plates
Start to use disks from a new manufacturer
Expand or reduce the dilution range in MIC testing
Repair of instrument that affects the AST results
5 Start to use prepared agar plates (disk diffusion), broth or
agar (MIC) from a new manufacturer
Convert inoculum preparation/standardization method
from visual adjustment of turbidity to use a photometric
device which has its own QC protocol
Update of the software which affects the AST results
20 or 30 Use new method for MIC test (e.g., convert from visual
reading to instrument reading of panel, convert from
overnight to rapid MIC test)
Use new manufacturer of MIC test
Change method of measuring zones in disk diffusion test
(e.g., start using an automated zone reader)
Convert inoculum preparation/standardization method to
a method that is dependent on user technique
* Number of days of consecutive QC testing required
Table 2. Required Quality Control Frequency after Modifications in the Test
For both, disk diffusion and MIC testing, addition of any new antimicrobial agent to the ex‐
isting panel requires 20 or 30 consecutive days of satisfactory testing before it can be tested
on a weekly schedule.
3.7. Corrective action
Corrective action is defined as the “action to eliminate the cause of a detected nonconformi‐
ty or other undesirable situation“ [28] and in regard to AST, is needed whenever any of the
weekly QC results are not within the acceptable limits. The factors causing for the deviation
in the results are various but can be divided in two as being results due to identifiable errors
and results with no error identified [24, 25]. Identifiable errors, also named obvious errors,
are easy to detect and also easy to correct. Most usual reasons causing for identifiable errors
include; use of the wrong disk, use of the wrong QC strain, contamination of the strain or
media, use of the wrong incubation temperature or conditions. If the reason causing the out-
of-range results is one of the identifiable errors, the test must be carried out again the day
the error is observed. If results of the repeat test are in acceptable limits, no further correc‐
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tive action is necessary. On the other hand, if the reason causing for the error cannot be
identified, the test must be carried out again the day the error is observed, preferably with a
new working culture or subculture, but should also be monitored for a total of five consecu‐
tive test days. During five consecutive days, if all results are within the acceptable limits no
additional corrective action is required. However, if any of the results are outside the accept‐
able limits, additional corrective action is required. At this point, a systematic error, rather
than a random should be suspected and the components of AST should be thoroughly in‐
vestigated. The reasons include; wrong measurement, clerical errors, problems in the adjust‐
ment of turbidity, past expiration date materials, failure in providing proper growth
conditions (temperature, atmosphere), improper storage of disks, contamination of QC
strain, loss of characteristics, inoculum prepared from an old plate (> 24 hours), etc.. In order
to start to routine QC testing, satisfactory performance for another 20 or 30 consecutive days
is required once the reason causing the error is detected and corrected.
When an out-of-range QC results necessitates a corrective action, the factors listed in Table 3
should be considered for troubleshooting (Table 3., adapted from references 24 and 25).
QC Strain Use of the wrong QC strain
Improper storage
Inadequate maintenance (e.g., use of the same working culture for
>1 month)
Contamination
Nonviability
Changes in the organisms (e.g., mutation, loss of plasmid)
Testing supplies Improper storage or shipping conditions
Contamination
Use of a defective agar plate (too thick or too thin)
Inadequate volume of broth in tubes or wells
Use of damaged plates, panels, cards, tubes (e.g., cracked, leaking)
Use of expired materials
Testing process Use of the wrong incubation temperature or conditions
Inoculum suspensions were incorrectly prepared or adjusted
Inoculum prepared from a plate incubated for the incorrect length
of time
Inoculum prepared from differential or selective media containing
anti-infective agents or other growth-inhibiting compounds
Use of wrong disk/reagents, ancillary supplies
Improper disk placement (e.g., inadequate contact with the agar)
Incorrect reading or interpretation of test results
Transcription error
Equipment Not functioning properly or out of calibration (e.g., pipettes)
Table 3. Factors Frequently Causing Out-of-range Results
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3.8. Documentation of the quality control test results
Results from all QC tests should be documented on a QC log sheet [23]. On this log sheet
information regarding the following are required: the date, the technician who performed
the test, antimicrobial agents used (potency, lot, expiration date, etc.), media used (lot, expi‐
ration date, etc.). Once the log sheet has been filled by the technician who performed and
read the test, a second technician, or the supervisor, should check the results. Also, correc‐
tive actions taken, if any, and their outcomes should be noted.
A useful and simple way of monitoring QC results is to use the Shewhart diagram, in which
the daily readings are plotted on a chart with upper and lower control limits marked [29]. It
provides the visual assessment of the results but can also provide in depth information if a
more formal mathematical approach is followed [20]. An example of presenting daily QC re‐
sults on a Shewhart diagram is given in Figure 1. The famous rules of Westgard and Klee
[30] can be easily adopted to the QC of disk diffusion test in which the control diameters are
treated as mean ±2 SD [20].
One QC result lies outside the limits (Westgard rule 12s): It is a warning, whether it’s a ran‐
dom error or the beginning of an emerging problem. Routine test results for that day may be
reported if there is no other evidence of problems in the current tests. It does not require
corrective action by itself, unless the result is far out of range or there are other indications
of a problem.
Two consecutive QC results are outside the limits in the same side of the mean of the range
(Westgard rule 22s): Indicates an error in the test methodology (a systematic error), corrective
action is required.
Ten consecutive QC results falling on one side of the mean (Westgard rule 10Ẍ): Results may
be accepted but this likely indicates a systematic problem which should be acted on.
Figure 1. Example for daily disk diffusion QC results for Escherichia coli ATCC® 25922 vs. ampicillin plotted on a She‐
whart diagram (acceptable zone limits: 16 – 22 mm).
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3.9. Organism - Antimicrobial susceptibility test result verification
One of the most widely used supplemental QC measure is the use of susceptibility test re‐
sults to verify results generated on patient results. Species with „typical“ antibiograms are
useful in verification of the identification as well as the susceptibility results. CLSI suggests
some results to be confirmed before they are reported, these mostly include rare resistance
phenotypes. The rare resistance phenotypes are divided in three categories; Category I; not
reported or only rarely reported to date, Category II; uncommon in most institutions, and
Category III; may be common, but is generally considered of epidemiological concern. Since
category I includes the least encountered and most significant results, it is highly important
to detect these results before being reported unnoticed and to follow the necessary steps for
the verification. Unusual resistance phenotypes which require confirmation are given in Ta‐
ble 3 (adapted from reference 2).
Category Observed susceptibility result
I NS to carbapenems, extended-spectrum cephalosporins or
fluoroquinolones in H. influenzae
NS to extended-spectrum cephalosporins, meropenem or
minocycline, R to ampicillin or penicillin in N. meningitidis
NS to linezolid or vancomycin in S. pneumoniae
NS to ampicillin, penicillin, extended-spectrum
cephalosporins, daptomycin, ertapenem, meropenem,
linezolid or vancomycin in β-hemolytic group
Streptococcus
NS to daptomycin, ertapenem, meropenem, linezolid, or
vancomycin, R to quinupristin-dalfopristin in viridans
group Streptococcus
II I or R to carbapenems in Enterobacteriaceae
I or R to 3rd generation cephalosporins or
fluoroquinolones in Salmonella and Shigella spp.
R to colistin/polymyxin in A. baumannii
I or R to colistin/polymyxin in P. aeruginosa
I or R to trimethoprim-sulfamethoxazole in S. maltophilia
R to amoxicillin-clavulanic acid, R to ampicillin without
accompanying β-lactamase production in H. influenzae
NS to extended spectrum cephalosporins in N.
gonorrhoeae
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Category Observed susceptibility result
I to ampicillin, penicillin, I or R to rifampin, NS to
azithromycin in N. meningitidis
R to linezolid, NS to daptomycin for Enterococcus spp.
NS to daptomycin, R to linezolid, I or R to quinupristin-
dalfopristin, vancomycin MIC = 4 µg/mL or vancomycin
MIC ≥ 8 µg/mL for S. aureus
NS to daptomycin, I or R to quinupristin-dalfopristin or
vancomycin, R to daptomycin in coagulase-negative
Staphylococcus spp.
I or R to fluoroquinolone, imipenem, meropenem,
quinupristin-dalfopristin, rifampin in S. pneumoniae
I or R to quinupristin-dalfopristin in β-hemolytic group
Streptococcus
III R to amikacin, gentamicin, and tobramycin in
Enterobacteriaceae
I or R to extended spectrum cephalosporins in E. coli,
Klebsiella spp. or P. mirabilis
I or R to carbapenem in A. baumannii
R to amikacin, gentamicin, and tobramycin, or
carbapenem in P. aeruginosa
I or R to fluoroquinolone in N. gonorrhoeae
I or R to chloramphenicol or fluoroquinolone in N.
meningitidis
R to vancomycin or high-level aminoglycoside in
Enterococcus spp.
R to oxacillin in S. aureus
R to amoxicillin, penicillin or extended spectrum
cephalosporins in S. pneumoniae using nonmeningitis
breakpoints
NS; nonsusceptible, I; intermediate, R; resistant
Table 4. Unusual Resistance Phenotypes Which Require Confirmation
The general approach to be followed is, for all three categories, to confirm the identification
of the organism and the AST. If the results are confirmed, the infection control should be
informed about the case.
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3.10. Real-time review of results
Accuracy of the susceptibility test results should be continously monitored. This is mostly
accomplished by daily reviewing of the data that is being produced. Profiles which are like‐
ly, somewhat likely, somewhat unlikely and nearly impossible should be identified, wheth‐
er manually or with the help of a software programmed to recognize different patterns of
susceptibility data [1]. Prompt recognition of unusual resistance or inconsistent susceptibili‐
ty helps the laboratory to timely confirm the susceptibility results. In order to confirm the
results, first step is to exclude the transcriptional and reading errors and make sure of the
purity of the inoculum which has been tested. If no errors are found in the previous steps,
the identification of the organism should be confirmed and the susceptibility test be repeat‐
ed, preferably with another method. In cases where no errors are detected and the unusual
resistance is confirmed, the clinician may be warned and measures can be taken to limit the
spread of this unusual resistance.
3.11. Education
Education is an important component of the QA process. Having knowledge about the
methods also provides the understanding of their limitations and pitfalls. A well-educated
technician may timely recognize atypical results and is aware of the approach to follow for
the resolution and avoidance of errors [20]. A very efficient way of training in-service per‐
sonnel is the end-point interpretation control [24, 25]. Laboratory workers, who perform
AST, are provided with a set of selected disk diffusion plates and are asked to read the re‐
sults. The recorded results are then compared by an experienced reader, e.g., the laboratory
director, and the individual performances of each technician is evaluated and if necessary,
corrected. It significantly helps to minimize variation in the interpretation of zone sizes
among laboratory workers.
3.12. External quality assessment
In external quality assessment (EQA) programs, a central laboratory distributes test strains
with known susceptibility profiles to all participant laboratories. Each participating labora‐
tory tests and reports the results to the central laboratory. Once all the results are returned
from participants, the central laboratory evaluates the results and prepares a feedback re‐
port. The benefit of participating in such program is that each individual laboratory can as‐
sess ist own performance compared with other laboratories, at national and international
levels, it functions as an educational tool, and also provides the evidence of performance re‐
quired by the accrediting bodies. On the other hand, the number of strains distributed in a
year is relatively small, which brings the disadvantage of the rare errors going unnoticed
[20]. Also, in contrast to internal QC, which is capable of acting on problems encountered on
daily basis, it takes quite a while for the EQA feedback reports to be sent to the participating
laboratories, thus corrective action is delayed.
3.13. Internal quality assessment
Internal quality assessment (IQA) is a complementary activity to EQA in which routine tests
are repeated on the same day as the original, but this time, with the identity of the specimen
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blinded. After the reports are produced, the results are compared and discrepancies noted.
This activity helps to monitor the precision and accuracy of the test procedure and may
highlight problem areas not detected by other QC methods. It monitors not only the per‐
formance of the test and reagents, but also the performance of the persons carrying out the
tests [20]. The EQA and the IQA are complementary activities, while IQA focuses on moni‐
toring a single laboratory on a daily basis, EQA compares the performance of different labo‐
ratories and is important for maintaining long-term accuracy of the AST methods employed
[21].
3.14. Proficiency testing programs
They are a type of EQA in which simulated patient specimens are sent to participating labo‐
ratories. Again, the reports are produced by each laboratory, and returned to the central lab‐
oratory for evaluation. In the United States, government mandates that clinical laboratories
be accredited and licensed. The government and licensing agencies are using proficiency
testing as an objective method for the accreditation of laboratories [21]. In 1988, the U.S.
Congress passed the Clinical Laboratory Improvement Amendment (CLIA ‘88) which man‐
dated proficiency testing (PT) as a major part of the laboratory accreditation process [31].
The initial CLIA ’88 proposal called for two PT specimens per year but final legislative rule,
published in 2003, expanded this to study five samples three times per year. The definition
of failure is defined as two of five incorrect results on two of the three consecutive PT sur‐
veys [32].
4. Quality control of automated antimicrobial susceptibility test systems
According to the work load and the resources a laboratory has, a laboratory can choose to
use one of many types of commercial automated antimicrobial susceptibility test systems.
Most of these systems use the principle of turbidimetric detection of bacterial growth in a
broth medium by use of a photometer which periodically examines the test wells [26]. The
most widely used systems in the world are VITEK 2 System (bioMérieux Vitek, Hazelwood,
MO), BD Phoenix System (BD Diagnostic Systems, Sparks, MD), MicroScan WalkAway SI
(Siemens Healthcare Diagnostics, Sacramento, CA) and TREK Sensititre (ARIS 2X, Trek Di‐
agnostic Systems, Cleveland, OH). Each device has its own QC procedure and commercial
susceptibility testing devices are not addressed in CLSI standards. CLSI only describes
methods regarding generic reference procedures, however these reference methods are used
by the US Food and Drug Administration before clearence is given to a commercial system
for marketing in the US to evaluate its performance.
5. Conclusion
Although great improvement has been done in AST methodology and automated suscepti‐
bility systems have been introduced which provide same-day results, it should be consid‐
ered that there are still many variables not covered by the standard methods. First of all, the
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laboratory test conditions are far different from in vivo conditions where the organism and
the antimicrobial agent do actually interact. Factors, such as bacterial inoculum size, pH, cat‐
ion concentration and oxygen tension differ greatly depending on the site of infection [1]. In
spite of all these limitations, the clinical microbiology laboratory should follow the most up-
to-date guidelines to serve the patients in the best possible way. With a well constructed QA
program in operation, a laboratory should aim to ensure that the right test is carried out on
the right specimen, and that the right result and right interpretation is delivered to the right
person at the right time.
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